The
department said it was taking the step as it was unable to
verify the legitimacy and reliability of those entities in
relation to their use of U.S. exports. The entities included
listed companies, universities as well as aerospace and
electronics suppliers.
China's commerce ministry hit out at the U.S. decision, saying
on Tuesday Washington should correct its "wrongdoings" and the
United States should return to the track of cooperation and
contribute more to the global economic recovery.
Stock in WuXi Biologics, whose units in Wuxi and Shanghai were
added to the unverified list, plummeted more than 25% on Tuesday
to wipe HK$77 billion ($9.9 billion) off its market value. Trade
in shares of the company, which makes ingredients for vaccines
including AstraZeneca's COVID-19 vaccine, was later halted.
WuXi Bio said that while it had imported manufacturing equipment
subject to U.S. export controls, Washington's move would have no
impact on its business or ongoing services to global partners.
CEO Chris Chen told an investor call on Tuesday that WuXi Bio
was prevented by U.S. export controls from reselling or
re-exporting items purchased from the United States but that the
Commerce Department had been unable to conduct checks that WuXi
Bio was in compliance due to the pandemic.
"Because of COVID-19, they have not been able to travel here in
the last two years to verify us, so they have put us on this
'unverified list'," he said.
"The affected companies are only in Shanghai and Wuxi and our
factories in Shanghai and Wuxi have already been built, so there
is no longer any need to buy large amounts of hardware for
bioreactors."
The company's lawyers plan to negotiate with the U.S. Commerce
Department, he added.
Shares in Hymson, a manufacturer of laser and automation
equipment, slid more than 7% after a unit was added to the list.
Hymson said in a statement that the addition would not have any
significant or adverse effect on its operations or financial
situation. It added that it would evaluate what impact the
listing could have on the company's future development.
($1 = 7.7947 Hong Kong dollars)
(Reporting by David Brunnstrom and Doina Chiacu; Additional
reporting by Roxanne Liu, Brenda Goh and Jason Xue; Editing by
Louise Heavens, Catherine Evans and Bernadette Baum)
[© 2022 Thomson Reuters. All rights
reserved.]
This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|
|